Langilan, Chrisly C.
HRN: 23-58-75 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/27/2023
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
08/27/2023
08/30/2023
PO
3ml
BID
Abrasions
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes